Outlook Therapeutics Inc. (OTLK) is on the brink of a make-or-break juncture that could pave the way for unprecedented growth and innovation within the company. With the FDA's Prescription Drug User Fee Act (PDUFA) goal date set for December 31, 2025, the spotlight is firmly on the company's leading product candidate, ONS-5010/LYTENAVA (bevacizumab-vikg).
This treatment is currently undergoing its final review for potential approval in addressing wet age-related macular degeneration (AMD).
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.